ライフサイエンスコーパス: relapse prevention

1 ed memories and has the potential to enhance relapse prevention.

2 elated projection and a potential target for relapse prevention.

3 lutamate receptor 2 should be considered for relapse prevention.

4 thium maintenance may be most beneficial for relapse prevention.

5 e)) is clinically used in many countries for relapse prevention.

6 mmunosuppression is the standard of care for relapse prevention.

7 BNST PACAP systems may be viable targets for relapse prevention.

8 f ongoing cocaine abuse but may be useful in relapse prevention.

9 control of infections, GVHD, engraftment and relapse prevention.

10 sleep hygiene, cognitive restructuring, and relapse prevention.

11 EC consisted of 3 family sessions focused on relapse prevention.

12 en systematically assessed as a strategy for relapse prevention.

13 enia, negative symptoms, loss of insight and relapse prevention.

14 ted with the greatest benefit with regard to relapse prevention.

15 II mGluRs as promising treatment targets for relapse prevention.

16 intaining long-term clinical response and in relapse prevention.

17 em to be particularly effective in promoting relapse prevention.

18 tive case management and skills training for relapse prevention.

19 s with schizophrenia that are independent of relapse prevention.

20 functioning, above and beyond the effects of relapse prevention.

21 g reduction, and maternal postpartum smoking relapse prevention.

22 as partially but not wholly mediated through relapse prevention.

23 ptide (NOP) receptors will have utility as a relapse prevention agent for multiple types of drug abus

24 on maintaining long-term abstinence, making relapse prevention an essential therapeutic goal.

25 In addition to relapse prevention and psychiatric symptom relief, the b

26 Despite clear evidence for their efficacy in relapse prevention and symptom relief, their effect on s

27 ed to bupropion or placebo for 6 months (for relapse prevention) and smoking participants were eligib

28 therapy that addresses only substance abuse (relapse prevention) and with standard community care for

29 ite receiving fewer treatment sessions, less relapse prevention, and less continuous care.

30 Seeking safety and relapse prevention are efficacious short-term treatments

31 a pharmacotherapeutic target for craving and relapse prevention associated with cocaine cue exposure.

32 fluoxetine monotherapy may provide superior relapse-prevention benefit relative to lithium monothera

33 Continuation-phase relapse-prevention CBT was effective in reducing the ris

34 retrieval-extinction procedure has superior relapse prevention characteristics than the CS memory re

35 e-blind, placebo-controlled, parallel-group, relapse-prevention clinical trial conducted in 10 commun

36 uential treatment strategy of fluoxetine and relapse-prevention cognitive-behavioral therapy (CBT) to

37 clinician; motivational enhancement therapy; relapse prevention counseling; and on-site medical, addi

38 Relapse prevention delayed time to first drug use at 6-m

39 ls that measured maternal postpartum smoking relapse prevention demonstrated a significant overall in

40 the first-line treatment when prescribing a relapse-prevention drug in patients with bipolar disorde

41 bo-controlled studies that have examined the relapse-prevention efficacy of maintenance therapy.

42 erapy appears efficacious as a treatment for relapse prevention for those with recurrent depression,

43 s evaluated included contingency management, relapse prevention, general cognitive behavior therapy,

44 conclusion that CT specifically designed for relapse prevention in bipolar affective disorder is a us

45 he efficacy and acceptability of lithium for relapse prevention in bipolar disorder.

46 than monotherapy with either drug alone for relapse prevention in bipolar I disorder.

47 y and safety of olanzapine as monotherapy in relapse prevention in bipolar I disorder.

48 of heroin and may be useful as an adjunct to relapse prevention in detoxified opioid-dependent subjec

49 tor may be useful in the future treatment of relapse prevention in drug addiction through memory reco

50 Even more effective strategies for relapse prevention in mood disorders are urgently needed

51 Approaches as used for relapse prevention in psychosis or for chronic at-risk s

52 Relapse prevention in recurrent depression is a signific

53 t-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia.

54 his article outlines a practical approach to relapse prevention in the primary care setting.

55 We hypothesized that a relapse prevention intervention would improve adherence

56 and 87 met abstinence criteria to enter the relapse prevention intervention.

57 ice and a nurse-managed cognitive behavioral relapse-prevention intervention at bedside, with telepho

58 Relapse prevention is important, but it should be sustai

59 Mindfulness-based relapse prevention (MBRP), a group-based psychosocial af

60 indicate possible neurochemical targets for relapse-prevention medication.

61 particular, in posthospitalization care and relapse prevention of adult anorexia nervosa.

62 nd of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking a

63 d on OFC throughout the study, including the relapse-prevention phase (up to 47 weeks).

64 abstinence at study week 52, the end of the relapse-prevention phase, confirmed by exhaled carbon mo

65 Sixty-one participants completed the relapse-prevention phase; 26 discontinued participation

66 ng of symptoms, and development of a written relapse prevention plan.

67 Maintenance treatment and relapse-prevention planning (summarization of early warn

68 phone, addressed satisfaction with outcomes, relapse-prevention planning, self-monitoring, and social

69 primary care physicians were randomized to a relapse prevention program (n = 194) or usual primary ca

70 A relapse prevention program targeted to primary care pati

71 This study examined whether a program for relapse prevention (PRP) is more effective than treatmen

72 es social skills but has no clear effects on relapse prevention, psychopathology, or employment statu

73 mipramine hydrochloride combined with weekly relapse prevention psychotherapy.

74 based interventions and cognitive-behavioral relapse prevention (RP) approaches.

75 eks (TEL), twice-weekly cognitive-behavioral relapse prevention (RP), and twice-weekly standard group

76 8) that emphasized motivational enhancement, relapse prevention, social skills training, and psychoed

77 ible individuals coupled with posttransplant relapse prevention strategies.

78 tudies were short term (</=4 months), and no relapse prevention studies or continuation phase studies

79 The authors report results from the first relapse prevention study in body dysmorphic disorder.

80 We believe this is the first controlled relapse-prevention study in subjects with TRD that suppo

81 n, structured psychotherapy, and maintenance/relapse prevention support.

82 ium has the strongest evidence for long-term relapse prevention; the evidence for anticonvulsants suc

83 f interest for the development of drug abuse relapse prevention therapies or antidepressants and othe

84 Relapse-prevention therapies attempt to interfere with d

85 received seeking safety therapy, 34 received relapse prevention therapy, and 32 received standard com

86 All participants received twice-weekly relapse prevention therapy, provided observed urine samp

87 outcome in women with anorexia nervosa in a relapse-prevention trial.

88 Strategies for relapse prevention using primaquine are reviewed.

89 n treating alcoholism from the standpoint of relapse prevention using psychosocial interventions alon

90 istered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine

91 ed responses could play an important role in relapse prevention, we examined whether baclofen-a GABAB

92 behavioral activation, exposure therapy, and relapse prevention, with optional chapters on sleep and